Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
120%(6 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_3
2
33%
Ph phase_2
4
67%

Phase Distribution

0

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
4(66.7%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Terminated(1)

Detailed Status

Completed5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (66.7%)
Phase 32 (33.3%)

Trials by Status

terminated117%
completed583%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules

NCT04440176
terminatedphase_2

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

NCT04645966
completedphase_3

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

NCT03135834
completedphase_3

MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age

NCT04440163
completedphase_2

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

NCT02212457
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04440176Phase 2

A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules

Completed
NCT04645966Phase 2

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

Terminated
NCT03135834Phase 3

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

Completed
NCT04440163Phase 3

MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age

Completed
NCT02212457Phase 2

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

Completed
NCT02140762Phase 2

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Completed

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6